SS
SMMT icon

SBI Securities’s Summit Therapeutics SMMT Stock Holding History

SBI Securities’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.32K Buy
434
+142
+49% +$2.52K ﹤0.01% 2065
2026
Q1 		$5.54K Buy
292
+3
+1% +$49 ﹤0.01% 1986
2025
Q4 		$5.05K Buy
289
+81
+39% +$1.52K ﹤0.01% 2017
2025
Q3 		$4.3K Sell
208
-1,548
-88% -$37.5K ﹤0.01% 2111
2025
Q2 		$37.4K Buy
1,756
+447
+34% +$10.2K ﹤0.01% 1167
2025
Q1 		$25.3K Buy
1,309
+88
+7% +$1.76K ﹤0.01% 1244
2024
Q4 		$21.8K Buy
+1,221
New +$23.7K ﹤0.01% 1307

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

SBI Securities's SMMT Position: Q2 2026 in Review

SBI Securities increased its Summit Therapeutics (SMMT) stake by 49% in Q2 2026, buying an estimated $2.52K and bringing the position to 434 shares worth $6.32K. The position accounts for ﹤0.01% of the portfolio, ranked #2065.

SBI Securities first reported a position in SMMT in Q4 2024 and has held it in 7 quarters since. The position peaked at $37.4K in Q2 2025. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • SBI Securities held 434 shares of Summit Therapeutics worth $6.32K as of Q2 2026.
  • SBI Securities bought 142 Summit Therapeutics shares in Q2 2026, an estimated $2.52K.
  • Summit Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #2065 holding.
  • SBI Securities first reported a position in Summit Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • SBI Securities's Summit Therapeutics position peaked at $37.4K in Q2 2025.
  • 242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.